BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) filed an Investigational New Drug (IND) application for ARRY-380 with the U.S. Food & Drug Administration and is now able to proceed with a Phase 1 clinical trial in cancer patients. ARRY-380, a selective, orally-active ErbB-2 inhibitor, has shown good efficacy in preclinical models of human breast cancer resulting in significant anti-tumor activity.
